|
2020
|
Invention
|
Glucokinase activator compositions for the treatment of diabetes. The present invention relates t... |
|
2019
|
Invention
|
Treatment of mild and moderate alzheimer's disease.
The present invention relates to methods of ... |
|
2018
|
Invention
|
Substituted imidazole derivatives and methods of use thereof. The present invention provides inte... |
|
|
Invention
|
Compositions comprising metformin and a glucokinase activator. The present invention provides use... |
|
2017
|
Invention
|
Use of metformin in combination with a glucokinase activator and compositions comprising metformi... |
|
2015
|
Invention
|
Phenylglyoxylic acid derivatives and their preparation and use.
The invention provides novel phe... |
|
|
Invention
|
Methods of treatment using fusion proteins.
The invention relates to method of treatment using f... |
|
|
Invention
|
Substituted azoanthracene derivatives and intermediates for preparation thereof. The present inve... |
|
2014
|
Invention
|
Oxadiazoanthracene compounds for the treatment of diabetes. The present invention provides method... |
|
|
Invention
|
Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compos... |
|
|
Invention
|
Phenyl-heteroaryl derivatives and methods of use thereof. The present invention provides phenyl-h... |
|
2013
|
Invention
|
Treatment of mild and moderate alzheimer's disease. The present invention relates to methods of t... |
|
|
Invention
|
Substituted imidazole derivatives and methods of use thereof. The present invention provides imid... |
|
|
Invention
|
Phenylglyoxylic acid derivatives and their preparation and use. The invention provides novel phen... |
|
2012
|
Invention
|
Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. T... |
|
2011
|
Invention
|
Nucleic acid molecules encoding rage fusion proteins. H2 domain. Also disclosed are RAGE fusion p... |
|
|
Invention
|
Rage fusion proteins and methods of use. H2 domain. Such fusion proteins may provide specific, hi... |
|
2010
|
Invention
|
Crystalline forms of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-pr... |
|
|
Invention
|
Rage fusion protein compositions and methods of use.
Disclosed are fusion proteins comprising a ... |
|
|
Invention
|
Probes, systems, and methods for drug discovery.
Aspects of the present invention include probes... |
|
|
Invention
|
N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the ... |
|
|
Invention
|
Control of rage fusion protein glycosylation and rage fusion protein compositions. The invention ... |
|
|
Invention
|
Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors. The present ... |
|
|
Invention
|
Substituted imidazole derivatives, compositions, and methods of use as ptpase inhibitors. The pre... |
|
2009
|
Invention
|
Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use. Substitut... |
|
|
Invention
|
Ligands for the glp-1 receptor and methods for discovery thereof. Disclosed is the three-dimensio... |
|
|
Invention
|
Oxadiazoanthracene compounds for the treatment of diabetes. The present invention provides oxadia... |
|
2008
|
Invention
|
Crystalline forms of [3-(4- {2-butyl- 1 -[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)... |
|
|
Invention
|
Urea glucokinase activators. This application relates to novel urea glucokinase activators and us... |
|
2007
|
Invention
|
Azole derivatives and fused bicyclic azole derivatives as therapeutic agents. This invention prov... |
|
|
Invention
|
Benzamide glucokinase activators. The present invention relates to N-heteroaryl-benzamides, pharm... |
|
|
Invention
|
Rage fusion proteins, formulations, and methods of use thereof. H2 domain. Also disclosed are RAG... |
|
2006
|
Invention
|
Dicycloalkyl urea glucokinase activators. Dicycloalkyl urea glucokinase activators compounds are ... |
|
2005
|
Invention
|
Heteroaromatic glucokinase activators. The present invention describes 2,3-di-substituted N-heter... |
|
|
Invention
|
Rage fusion proteins. H2 domain. Such fusion proteins may provide specific, high affinity binding... |
